EWTX insider transactions
Edgewise Therapeutics Inc. (EWTX) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
Recent Form 3, 4, and 5 filings for EWTX
- SEC Form 4 filed by Fox Jonathan C4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- SEC Form 4 filed by Donovan Joanne M.4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- SEC Form 4 filed by Donovan Joanne M.4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- SEC Form 4 filed by Donovan Joanne M.4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- Director Edris Badreddin exercised 115,471 shares at a strike of $1.47 and sold $3,399,466 worth of shares (115,471 units at $29.44) (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- Director Fox Jonathan C was granted 473 shares, increasing direct ownership by 2% to 24,175 units (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- SEC Form 4 filed by Director Martin Christopher Nathan4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- SEC Form 3 filed by new insider Martin Christopher Nathan3 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- Chief Scientific Officer Russell Alan J exercised 100,000 shares at a strike of $0.18 and sold $2,112,450 worth of shares (100,000 units at $21.12) (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- Director Fox Jonathan C bought $199,403 worth of shares (10,700 units at $18.64), increasing direct ownership by 82% to 23,702 units (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- SEC Form 4 filed by Chief Financial Officer Nofi Michael4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- SEC Form 3 filed by new insider Nofi Michael3 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- Director Fox Jonathan C was granted 728 shares, increasing direct ownership by 6% to 13,002 units (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- Chief Scientific Officer Russell Alan J exercised 100,000 shares at a strike of $0.18 and sold $1,459,760 worth of shares (100,000 units at $14.60) (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- SEC Form 4 filed by Chief Development Officer Blaustein Robert4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- General Counsel Moore John R converted options into 5,781 shares and sold $28,097 worth of shares (2,098 units at $13.39), increasing direct ownership by 56% to 10,214 units (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- Chief Business Officer Derakhshan Behrad converted options into 5,781 shares and sold $33,360 worth of shares (2,491 units at $13.39), increasing direct ownership by 16% to 23,645 units (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- Chief Financial Officer Carruthers R Michael converted options into 5,781 shares and sold $19,124 worth of shares (1,428 units at $13.39), increasing direct ownership by 5% to 86,162 units (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- Chief Scientific Officer Russell Alan J converted options into 5,781 shares and sold $25,539 worth of shares (1,907 units at $13.39), increasing direct ownership by 20% to 23,400 units (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- President and CEO Koch Kevin converted options into 17,968 shares and sold $106,764 worth of shares (7,972 units at $13.39), increasing direct ownership by 48% to 30,615 units (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- CMO Donovan Joanne M. converted options into 5,781 shares and sold $38,329 worth of shares (2,862 units at $13.39), increasing direct ownership by 13% to 25,361 units (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- Director Fox Jonathan C was granted 858 shares, increasing direct ownership by 8% to 12,274 units (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- SEC Form 4 filed by Director Brege Laura4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- SEC Form 4 filed by Director Edris Badreddin4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- SEC Form 4 filed by Director Morris Arlene4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- SEC Form 4 filed by Director Fox Jonathan C4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- SEC Form 4 filed by Director Root Jonathan D4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- SEC Form 4 filed by Director Thompson Peter A.4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- Chief Scientific Officer Russell Alan J converted options into 5,209 shares and sold $25,520 worth of shares (1,551 units at $16.45), increasing direct ownership by 25% to 18,521 units (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- General Counsel Moore John R converted options into 5,209 shares and sold $31,757 worth of shares (1,930 units at $16.45), increasing direct ownership by 101% to 6,531 units (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- President and CEO Koch Kevin converted options into 10,417 shares and sold $70,358 worth of shares (4,276 units at $16.45), increasing direct ownership by 42% to 20,619 units (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- CMO Donovan Joanne M. converted options into 10,417 shares and sold $85,348 worth of shares (5,187 units at $16.45), increasing direct ownership by 32% to 21,588 units (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- Chief Business Officer Derakhshan Behrad converted options into 5,209 shares and sold $27,824 worth of shares (1,691 units at $16.45), increasing direct ownership by 21% to 20,355 units (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- Chief Financial Officer Carruthers R Michael converted options into 5,209 shares and sold $21,621 worth of shares (1,314 units at $16.45), increasing direct ownership by 5% to 81,014 units (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- Director Thompson Peter A. bought $10,000,000 worth of shares (496,771 units at $20.13) (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- Director Orbimed Advisors Llc bought $10,000,000 worth of shares (496,771 units at $20.13) (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- Director Fox Jonathan C was granted 559 shares, increasing direct ownership by 5% to 11,416 units (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- Chief Scientific Officer Russell Alan J exercised 200 shares at a strike of $0.18 and sold $6,004 worth of shares (200 units at $30.02) (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- President and CEO Koch Kevin exercised 100 shares at a strike of $0.18 and sold $3,000 worth of shares (100 units at $30.00) (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- Chief Scientific Officer Russell Alan J exercised 9,215 shares at a strike of $0.18 and sold $276,776 worth of shares (9,215 units at $30.04) (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- President and CEO Koch Kevin exercised 9,536 shares at a strike of $1.40 and sold $287,316 worth of shares (9,536 units at $30.13) (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- Chief Business Officer Derakhshan Behrad exercised 10,000 shares at a strike of $1.93 and sold $300,300 worth of shares (10,000 units at $30.03) (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- CMO Donovan Joanne M. sold $690,658 worth of shares (25,000 units at $27.63) and exercised 25,000 shares at a strike of $7.08 (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- SEC Form 4 filed by Chief Development Officer Blaustein Robert4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- SEC Form 3 filed by new insider Blaustein Robert3 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- Chief Scientific Officer Russell Alan J exercised 100,000 shares at a strike of $0.18 and sold $2,737,470 worth of shares (100,000 units at $27.37) (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- Chief Development Officer Semigran Marc exercised 29,709 shares at a strike of $8.94 and sold $881,915 worth of shares (29,709 units at $29.69) (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- Chief Financial Officer Carruthers R Michael exercised 70,000 shares at a strike of $0.71, increasing direct ownership by 1,014% to 76,904 units (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- Chief Scientific Officer Russell Alan J exercised 75,000 shares at a strike of $0.18 and sold $2,120,101 worth of shares (75,000 units at $28.27) (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- General Counsel Moore John R exercised 70,922 shares at a strike of $0.71 and sold $1,996,574 worth of shares (70,922 units at $28.15) (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- CMO Donovan Joanne M. sold $202,603 worth of shares (7,162 units at $28.29), decreasing direct ownership by 33% to 14,538 units (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- Chief Business Officer Derakhshan Behrad exercised 42,068 shares at a strike of $1.93 and sold $1,221,133 worth of shares (42,068 units at $29.03) (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- Chief Financial Officer Carruthers R Michael exercised 96,068 shares at a strike of $1.93 and sold $3,573,980 worth of shares (125,092 units at $28.57), decreasing direct ownership by 81% to 6,904 units (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- SEC Form 4 filed by Chief Scientific Officer Russell Alan J4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- SEC Form 4 filed by Chief Development Officer Semigran Marc4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- SEC Form 4 filed by General Counsel Moore John R4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- SEC Form 4 filed by Chief Business Officer Derakhshan Behrad4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- SEC Form 4 filed by President and CEO Koch Kevin4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- SEC Form 4 filed by CMO Donovan Joanne M.4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- SEC Form 4 filed by Chief Financial Officer Carruthers R Michael4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)